Copyright
©The Author(s) 2021.
World J Hepatol. Sep 27, 2021; 13(9): 1181-1189
Published online Sep 27, 2021. doi: 10.4254/wjh.v13.i9.1181
Published online Sep 27, 2021. doi: 10.4254/wjh.v13.i9.1181
Outcome | Count (%) (95%CI) |
n = 8028 | |
History of liver disease | 245 (3.1) (2.7, 3.5) |
Death | 673 (8.4) (7.8, 9.0) |
Hospital admission | 5199 (64.8) (63.7, 65.8) |
Outcome | Count (%) (95%CI) |
n = 5199 | |
ICU admit | 807 (15.5) (14.6, 16.5) |
Intubation | 637 (12.3) (11.4, 13.2) |
Outcome | Count (%) (95%CI) |
Any elevated liver enzyme | 1722 (44.9) (43.3, 46.5) |
Elevated AST | 1297 (33.5) (32.0, 35.0) |
Elevated ALT | 1052 (26.7) (25.4, 28.2) |
Elevated AP | 392 (10.1) (9.2, 11.1) |
Elevated bilirubin | 468 (12.0) (11.0, 13.1) |
Any super elevated liver enzyme | 714 (18.6) (17.4, 19.9) |
Super elevated AST | 480 (12.4) (11.4, 13.5) |
Super elevated ALT | 468 (11.9) (10.9, 13.0) |
Super elevated AP | 94 (2.4) (1.9, 3.0) |
- Citation: Currier EE, Dabaja M, Jafri SM. Elevated liver enzymes portends a higher rate of complication and death in SARS-CoV-2. World J Hepatol 2021; 13(9): 1181-1189
- URL: https://www.wjgnet.com/1948-5182/full/v13/i9/1181.htm
- DOI: https://dx.doi.org/10.4254/wjh.v13.i9.1181